AMR SVG Icons location

niCARdipine Hydrochloride Injection, USP


  • Therapeutically equivalent to Cardene®*1
  • Preservative free
  • Vial closure is not made with natural rubber latex

Receive Availability Emails

  Pack NDC# Strength Supplied As Shelf Pack Product Info Availability
Strength:

2.5 mg/mL

Supplied As:

10 mL
Single Dose Vial  

NDC#: 0517-0735-10
0517-0735-10

2.5 mg/mL

10 mL
Single Dose Vial  

10 In Stock

Wholesaler Numbers

  • ABC/SAP 10235574
  • Cardinal 5642830
  • McKesson 1537034
  • Morris & Dickson 903203

Case Information

  • Unit of Sale NDC 0517-0735-10
  • Order Size 10
  • Case Size 36
  • Case Per Tier 80

* Cardene is a registered trademark Chiesi USA, Inc.
   1. Data on file. FDA Approval Letter ANDA 090534. Shirley, NY American Regent, Inc.  

Contact Us

Request a Grant Investigator Initiated Study Request a Certificate of Analysis Expanded Access Policy
Please choose your preferred method of contact

By clicking Submit, you confirm that you accept our Privacy Policy and that you agree to your personal contact information being used to contact you and added to our database. If at any time you wish your personal information to be removed from the American Regent database, please submit a message request to corpcommunications@americanregent.com.

niCARdipine Hydrochloride Injection, USP

For Intravenous Use

VIALS MUST BE DILUTED BEFORE INFUSION

INDICATIONS AND USAGE: Nicardipine hydrochloride injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits.

IMPORTANT SAFETY INFORMATION
Contraindications:
Do not use in patients with advanced aortic stenosis.

WARNINGS AND PRECAUTIONS

Closely monitor response in patients not limited to those with angina, heart failure, impaired hepatic function or renal impairment and avoid too rapid or excessive blood pressure drop during treatment.

Local Irritation

To reduce the possibility of venous thrombosis, phlebitis, local irritation, swelling, extravasation, and the occurrence of vascular impairment, administer drug through large peripheral veins or central veins. To minimize the risk of peripheral venous irritation, change the site of the drug infusion every 12 hours.

ADVERSE REACTIONS

Most common adverse reactions are headache (15%), hypotension (6%), tachycardia (4%) and nausea/vomiting (5%).

Post-Marketing

Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or to establish a causal relationship to drug exposure. The following adverse reaction has been identified during post-approval use of nicardipine hydrochloride injection: decreased oxygen saturation (possible pulmonary shunting).

USE IN SPECIFIC POPULATIONS

Pregnancy: Pregnancy Category C. Based on animal data may cause fetal harm.  Nicardipine hydrochloride injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing mothers: Minimally excreted into human milk. Consider the possibility of infant exposure.

Pediatric Use: Safety and efficacy in patients under the age of 18 have not been established.

OVERDOSAGE

For treatment of overdosage, implement standard measures including monitoring of cardiac and respiratory functions.

For additional safety information, please see Full Prescribing Information.

You are encouraged to report Adverse Drug Events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

REF-1429  3/2020